Machine learning hypothesis-generation for patient stratification and target discovery in rare disease: our experience with Open Science in ALS.

"Conflict of interest JG, BQ, PL, DC, and LP were employed by NetraMark Corp. JG declares that he owns substantial shares in NetraMark Holdings, which funded a major portion of this study. LP and DC are also shareholders in this company. LP’s disclosures (past 3 years): AbbVie, USA; Acadia, USA; Alexion, Italy; BCG, Switzerland; Boehringer Ingelheim International GmbH, Germany; Compass Pathways, UK; EDRA-LSWR Publishing Company, Italy; Ferrer, Spain; Gedeon-Richter, Hungary; GLG-Institute, USA; Immunogen, USA; Inpeco SA, Switzerland; Ipsen-Abireo, France; Johnson & Johnson USA; NeuroCog Trials, USA; Novartis-Gene Therapies, Switzerland; Sanofi-Aventis-Genzyme, France and USA; NetraMark, Canada*; Otsuka, USA; Pfizer Global, USA; PharmaMar, Spain; Relmada Therapeutics, USA*; Takeda, USA; Vifor, Switzerland; WCG-VeraSci/Clinical Endpoint Solutions, USA (*options / shares). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The authors declare that this study received funding from NetraMark Holdings and provided compensation to authors JG, BQ, PL, DC, and LP. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication."